Serum antibody screening using glycan arrays

Samantha Marglous, Claire E. Brown, Vered Padler-Karavani*, Richard D. Cummings*, Jeffrey C. Gildersleeve*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Humans and other animals produce a diverse collection of antibodies, many of which bind to carbohydrate chains, referred to as glycans. These anti-glycan antibodies are a critical part of our immune systems’ defenses. Whether induced by vaccination or natural exposure to a pathogen, anti-glycan antibodies can provide protection against infections and cancers. Alternatively, when an immune response goes awry, antibodies that recognize self-glycans can mediate autoimmune diseases. In any case, serum anti-glycan antibodies provide a rich source of information about a patient's overall health, vaccination history, and disease status. Glycan microarrays provide a high-throughput platform to rapidly interrogate serum anti-glycan antibodies and identify new biomarkers for a variety of conditions. In addition, glycan microarrays enable detailed analysis of the immune system's response to vaccines and other treatments. Herein we review applications of glycan microarray technology for serum anti-glycan antibody profiling.

Original languageEnglish
Pages (from-to)2603-2642
Number of pages40
JournalChemical Society Reviews
Issue number5
StatePublished - 2 Feb 2024


FundersFunder number
National Institutes of HealthR24GM137763
National Cancer Institute
European Research CouncilERC-2020-COG-101003021


    Dive into the research topics of 'Serum antibody screening using glycan arrays'. Together they form a unique fingerprint.

    Cite this